GELSYN-3

FDA Premarket Approval P110005 S012

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

DeviceGELSYN-3
Generic NameAcid, Hyaluronic, Intraarticular
ApplicantIBSA INSTITUT BIOCHIMIQUE SAvia Al Ponte 13, Ch-6903lugano Ticino 6903 PMA NumberP110005 Supplement NumberS012 Date Received09/08/2022 Decision Date10/07/2022 Product Code MOZ  Advisory Committee Orthopedic Supplement Typespecial (immediate Track) Supplement Reason Labeling Change - Indications/instructions/shelf Life/tradename Expedited Review Granted? No
Date Received2022-09-08
Decision Date2022-10-07
PMAP110005
SupplementS012
Product CodeMOZ 
Advisory CommitteeOrthopedic
Supplement TypeSpecial (immediate Track)
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination ProductNo
Applicant AddressIBSA INSTITUT BIOCHIMIQUE SA
via Al Ponte 13, Ch-6903
lugano Ticino 6903 PMA NumberP110005 Supplement NumberS012 Date Received09/08/2022 Decision Date10/07/2022 Product Code MOZ  Advisory Committee Orthopedic Supplement Typespecial (immediate Track) Supplement Reason Labeling Change - Indications/instructions/shelf Life/tradename Expedited Review Granted? No Combination ProductNo Approval Order Statement  
Approval For Revisions To The Adverse Reactions Section Of The Product Information And Patient Information Labeling Based On Post-market Adverse Event And Safety Data Collected Up To March 2022.

Supplemental Filings

Supplement NumberDateSupplement Type
P110005Original Filing
S012 2022-09-08 Special (immediate Track)
S011 2022-02-16 30-day Notice
S010
S009 2021-03-31 135 Review Track For 30-day Notice
S008 2021-03-03 30-day Notice
S007 2020-12-03 30-day Notice
S006 2020-09-04 30-day Notice
S005 2020-09-04 30-day Notice
S004 2020-06-29 Special (immediate Track)
S003 2018-04-09 Special (immediate Track)
S002 2017-01-19 Normal 180 Day Track
S001 2016-03-25 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.